Clinical Trial Update: A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluating huMAb OX40L for preventing allergen-induced airway obstruction in adults with mild allergic asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• huMAb OX40L (OX40L-targeting monoclonal antibody)

Snippet

Sponsor: Genentech, Inc. | Conditions: Asthma | Phase 2 | Status: COMPLETED